Pharmacogenetics of uncontrolled asthma



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This review summarizes the results of pharmacogenetic studies of determination response to drugs used for the treatment of bronchial asthma. Pharmacogenetic information will enable the use of a personalized approach to the asthma management, which will adjust the therapy technology and increase the possibility of achieving disease control.

Full Text

Restricted Access

About the authors

E S Kulikov

Siberian State Medical University

Email: evgeny.s.kulikov@gmail.com

L M Ogorodova

Siberian State Medical University

M B Freidin

Siberian State Medical University

I A Deev

Siberian State Medical University

A A Rudko

Siberian State Medical University

P A Selivanova

Siberian State Medical University

References

  1. Глобальная стратегия лечения и профилактики бронхиальной астмы. Под ред. А.Г. Чучалина. М.: Атмосфера. 2007, 104 с.
  2. Global Burden of Asthma Report [Электронный ресурс]. Электрон. дан. 2012. http://www.ginasthma.org/re-ports-global-burden-of-asthma.html.
  3. Janson C., Anto J., Burney P. et al. European Community Respiratory Health Survey II. The European Community Respiratory Health Survey: what are the main results so far? European Community Respiratory Health Survey II. Eur. Respir. J. 2001, v. 18, p. 598-611.
  4. Федосеев Г.Б., Емельянов А.В., Сергеева Г.Р. и соавт. Рас-пpостpаненность бpонхиальной астмы и аллеpгического pинита сpеди взpослого населения Санкт-Петеpбуpга. Терапевт. архив. 2003, № 1, с. 21-27.
  5. Ленская Л.Г, Огородова Л.М. Фармакоэкономика бронхиальной астмы. Общественное здоровье и организация медицинской помощи на рубеже веков. Томск. 2000, с. 77-83.
  6. Медников Б.Л. Экономические аспекты в пульмонологии. Хронические обструктивные болезни легких. М., Биномю. 1998, с. 501-510.
  7. Чучалин А.Г, Пыжева Е.С., Колганова Н.А. Социально-экономическая значимость заболеваемости бронхиальной астмой и ее стоимостное определение. Экономика здравоохраненияю 1997, № 4-5, с. 29-37.
  8. Koshak E.A. Classification ofasthma according to revised 2006 GINA: Evolution from severity to control. Ann. Thorac. Med. 2007, v. 2 (2), p. 45-46.
  9. Asthma in America survey — AIA: Executive summary [Электронный ресурс]. Электрон. дан. 1997—2010. http:// www.asthmainamerica.com.
  10. Asthma Insights and Reality in Eastern Europe — AIRCEE [Электронный ресурс]. Электрон. дан. 2004. http://www. asthmaineurope.co.uk.
  11. Lai C.K.W., de Guia T.S., Kim Y.Y et al. Asthma control in the Asia-Pacific region: The Asthma Insights and Reality in Asia-Pacific Study. J. Allergy Clin. Immunol. 2003, v. 111, p. 263-268.
  12. Chapman K.R., Boulet L.P., Rea R.M. et al. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur. Respir. J. 2008, v. 31 (2), p. 320-325.
  13. Klaus F., Mitsuru A., Christopher K.W. et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J. Allergy Clin. Immunol. 2004, v. 114, No. 1, p. 40-47.
  14. Neffen, H., Fritscher C., Schacht F.C. et al. Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) survey. Rev. Panam. Salud. Publica. 2005, v. 17(3), p. 191-197.
  15. Куликов Е.С. Стратегии достижения контроля в условиях реальной клинической практики. Данные многоцентрового исследования СТРЕЛА-АСТ Бюллетень сибирской медицины. 2009, № 4, с. 75-81.
  16. Огородова Л.М., Белевский А.С., Куликов Е.С. и соавт. Сравнительная эффективность стратегий достижения контроля в условиях реальной клинической практики: данные многоцентрового исследования СТРЕЛА. Пульмонология. 2009, № 6, с. 69-77.
  17. Куликов Е.С., Огородова Л.М., Белевский А.С. и соавт. Эффективность стратегий достижения и поддержания контроля над бронхиальной астмой в условиях реальной клинической практики: данные многоцентрового исследования СТРЕЛА-АСТ. Пульмонология. 2010, № 1, с. 80-86.
  18. Огородова Л.М., Куликов Е.С., Деев И.А. и соавт. Динамика функциональных показателей при применении различных схем лечения бронхиальной астмы: данные многоцентрового исследования СТРЕЛА-АСТ. Клиническая медицина. 2011, № 4, с. 36-41.
  19. Bergquist P., Crompton G.K. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur. Respir. J. 2001, v. 18 (1), p. 248.
  20. Wenzel S.E. Asthma: defining of the persistent adult phenotypes. Lancet. 2006, v. 368 (9537), p. 804-813.
  21. Moore W.C., Meyers D.A., Wenzel S.E. Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program. Am. J. Respir. Crit. Care Med. 2010, v. 18, p. 315-323.
  22. Bradding P., Green R.H. Subclinical phenotypes of asthma. Curr. Opin. Allergy Clin. Immunol. 2010, v. 10 (1), p. 54-59.
  23. Hall I.P. Genetics and pulmonary medicine 8: asthma. Thorax. 1999, v. 54 (1), p. 65-69.
  24. Bradley B.L., Azzawi M., Jacobson M. et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. Journal of Allergy and Clinical Immunology. 1991, v. 88, p. 661-674.
  25. Vercelli D. Discovering susceptibility genes for asthma and allergy. Nat. Rev. Immunol. 2008, v. 8, p. 169-182.
  26. Evans W.E., McLeod H.L. Pharmacogenomics — drug disposition, drug targets, and side effects. N. Engl. J. Med. 2003, v. 348, No. 6, p. 538-549.
  27. Drysdale C.M., McGraw D.W., Stack C.B. et al. Complex promoter and coding region beta 2adrenergic receptor haplo-types alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. USA. 2000, v. 97, No. 19, p. 10483-10488.
  28. Shin J., Kayser S.R., Langaee T. Pharmacogenomics: from discovery to patient care. Am. J. Health Syst. Pharm. 2009, v. 66, p. 625-637.
  29. Taussig R., Zimmermann G. Type-specific regulation of mammalian adenylyl cyclases by G protein pathways. Adv Second Messenger Phosphoprotein Res. 1998, v. 32, p. 81-98.
  30. Taylor S.S., Buechler J.A., Yonemoto W. сAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Ann. Rev. Biochem. 1990, v. 59, p. 971-1005.
  31. Reihsaus E., Innis M., Macintyre N., Liggett S.B. Mutations in the gene encoding for the b2-adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Cell Mol. Biol. 1993, v. 8 (3), p. 334-339.
  32. Israel E., Drazen J.M., Ligett S.B. et al. The effect of polymorphisms on the ß2adrenergic receptor on the response to regular use of albuterol in asthma. Am. J. Respir. Crit. Care Med. 2000, v. 162, p. 75-80.
  33. Israel E., Chinchilli V.M., Ford J.G. et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled crossover trial. Lancet. 2004, v. 364, p. 1505-1512.
  34. Metzger N.L., Kockler D.R., Gravatt L.A. Confirmed beta-16Arg/Arg polymorphism in a patient with uncontrolled asthma. Ann. Pharmacother. 2008, v. 42, No. 6, p. 874-881.
  35. Васьковский Н.В., Куликов Е.С. Механизмы нарушения контроля бронхиальной астмы при применении β2-агонистов. Бюллетень сибирской медицины. 2006, № 1, с. 67-72.
  36. Green S.A., Turki J., Vegarno P. et al. Influence of ß2adrenergic receptor genotypes on signal transduction in human airways smooth muscle cells. Am. J. Respir. Cell. Mol. Biol. 1995, v. 13, p. 25-33.
  37. Tan K.S., Hall I.P., Dewar J. et al. Association between ß2adrenoceptorpolymorhism and susceptibility to bronchodilator desensitization in moderately severe stable asthmatics. Lancet. 1997, v. 350, p. 995-999.
  38. Ligett S.B. Pharmacogenetics or ß1 and ß2adrenergic receptors. Pharmacol. 2002, v. 137, p. 1213-1216.
  39. Telleria J.J., Blanco-Quiros A., Muntion S. et al. Tachyphylaxis to ß2agonists in Spanish asthmatic patients could be modulated by ß2adrenoceptor gene polymorphisms. Respir. Med. 2006, v. 100, p. 1072-1078.
  40. Green S.A., Turki J., Innis M. et al. Amino-terminal polymorphism of the human ß2adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994, v. 33, p. 9414-9419.
  41. Lee M.Y., Cheng S.N., Chen S.J. et al. Polymorphisms of the b2-adrenergic receptor correlated to nocturnal asthma and the response of terbutaline nebulizer. Pediatr. Neonatol. 2011, v. 52 (1), p. 18-23.
  42. Basu K., Palmer C.N., Tavendale R. et al. Adrenergic b(2)-re-ceptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J. Allergy Clin. Immunol. 2009, v. 124 (6), p. 1188-1194.
  43. Bleecker E.R., Postma D.S., Lawrance R.M. et al. Effect of ADRB2 polymorphisms on response to longacting ß2-agonist therapy: a pharmacogenetic analysis of two randomized studies. Lancet. 2007, v. 370 (9605), p. 2118-2125.
  44. Bleecker E.R., Nelson H.S., Kraft M. et al. ß2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am. J. Respir. Crit. Care Med. 2010, v. 181 (7), p. 676-687.
  45. Wechsler M.E., Kunselman S.J., Chinchilli V.M. et al. Effect of b-adrenergic receptor polymorphism on response to longacting b2 agonist in asthma (LARGE trial): a genotype-stratified, randomized, placebocontrolled, crossover trial. Lancet. 2009, v. 374 (9703), p. 1754-1764.
  46. Panebra A., Schwarb M.R., Swift S.M. et al. Variable-length poly-C tract polymorphisms of the beta2-adrenergic receptor 30UTR alter expression and agonist regulation. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2008, v. 294, p. 190-195.
  47. Litonjua A.A., Lasky-Su J., Schneiter K. et al. ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts. Am. J. Respir. Crit. Care Med. 2008, v. 178 (7), p. 688-694.
  48. Vonk J.M., Postma D.S., Maarsingh H. et al. Arginase 1 and arginase 2 variations associate with asthma, asthma severity and ß2-agonist and steroid response. Pharmacogenet. Genomics. 2010, v. 20 (3), p. 179-186.
  49. Meurs H., Mckay S., Maarsingh H. et al. Increased arginase activity underlies allergen-induced deficiency of cNOSderived nitric oxide and airway hyperresponsiveness. Br. J. Pharmacol. 2002, v. 136 (3), p. 391-398.
  50. Maarsingh H., Zuidhof A.B., Bos I.S. et al. Arginase inhibition protects against allergen-induced airway obstruction, hyperresponsiveness, and inflammation. Am. J. Respir. Crit. Care Med. 2008, v. 178 (6), p. 565-573.
  51. Moore P.E., Ryckman K.K., Williams S.M. at al. Genetic variants of GSNOR and ADRB2 influence response to albuterol in African — American children with severe asthma. Pediatr. Pulmonol. 2009, v. 44 (7), p. 649-654.
  52. Choudhry S., Que L.G., Yang Z. et al. GSNO reductase and b2-adrenergic receptor gene—gene interaction: bronchodilator responsiveness to albuterol. Pharmacogenet. Genomics. 2010, v. 20 (6), p. 351-358.
  53. Gaston B., Reilly J., Drazen J.M. et al. Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc. Natl. Acad. Sci. USA. 1993, v. 90 (23), p. 10957-10961.
  54. Whalen E.J., Foster M.W., Matsumoto A. et al. Regulation of b-adrenergic receptor signaling by S-nitrosylation of G-proteincoupled receptor kinase 2. Cell. 2007, v. 129 (3), p. 511-522.
  55. Wechsler M.E., Lehman E., Lazarus S.C. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am. J. Respir. Crit. Care Med. 2006, v. 173 (5), p. 519-526.
  56. Sayers I., Hall I.P. Pharmacogenetic approaches in the treatment of asthma. Curr. Allergy Asthma Rep. 2005, v. 5 (2), p. 101-108.
  57. Tantisira K.G., Lake S., Silverman E.S. et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum. Mol. Genet. 2004, v. 13, p. 1353-1359.
  58. Ye Y.M., Lee H.Y., Kim S.H. et al. Pharmacogenetic study of the effects of NK2R G231E G>A and TBX21 H33Q C>G polymorphisms on asthma control with inhaled corticosteroid treatment. J. Clin. Pharm. Ther. 2009, v. 34 (6), p. 693-701.
  59. Hawkins G.A., Lazarus R., Smith R.S. et al. The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids. J. Allergy Clin. Immunol. 2009, v. 123 (6), p. 1376-1383.
  60. Tantisira K.G., Silverman E.S., Mariani T.J. et al. FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. J. Allergy Clin. Immunol. 2007, v. 120 (6), p. 1285-1291.
  61. Koster E.S., Maitland van der Zee A.H., Tavendale R. et al. FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children. Allergy. 2011, v. 66 (12), p. 1546-1552.
  62. Tantisira K.G., Lasky-Su J., Harada M. et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N. Engl. J. Med. 2011, v. 365 (13), p. 1173-1183.
  63. Kino T., Chrousos G.P. Glucocorticoid and mineralocorticoid resistance/hypersensitivity syndromes. J. Endocrinol. 2001, v. 169 (3), p. 437-445.
  64. Vottero A., Kino T, Combe H. et al. A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators. J. Clin. Endocrinol. Metab. 2002, v. 87 (6), p. 2658-2667.
  65. Huizenga N.A., Koper J.W., De Lange P. et al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J. Clin. Endocrinol. Metab. 1998, v. 83 (1), p. 144-151.
  66. Симакова М.А., Миронова Ж.А., Трофимов В.И. и соавт. «Терапевтическая резистентность» у больных тяжелой бронхиальной астмой. Пульмонология. 2010, № 2, с. 108-113.
  67. Mironova Z.A., Trofimov V.I., Simakova M.A. et al. Pharmacogenetic markers of steroid dependent bronchial asthma (BA) control. Europ. Respir. J. 2010, v. 36, 1003 p.
  68. Simakova M.A., Mironova Z.A., Trofimov V.I. et al. Association of C3435T polymorphism of MDR1 gene and T1808A polymorphism of NR3C1 gene with bronchial obstruction in severe asthmatics and COPD patients. Europ. Respir. J. 2010, v. 36, 779 p.
  69. Mironova Z.A., Trofimov V.I., Simakova M.A. et al. Allele variants of C3435T multidrug resistance gene (MDR1), R130Q interleukin 13 (IL13) gene, —590C>T interleukin-4 (IL-4) gene — markers of steroid dependent bronchial asthma (BA) risk. Europ. Respir. J. 2010, v. 36, p. 291-292.
  70. Mironova Z.A., Trofimov V.I., Ianchina E.D. et al. The associations of polymorphism C3435T multidrug resistance gene (MDR1) and regimen of inhaled glucocorticosteroid therapy in bronchial asthma (BA) patients. Europ. Respir. J. 2008, v. 32 (52), 633 p.
  71. Hakonarson H., Bjornsdottir U.S., Halapi E. et al. Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc. Natl. Acad. Sci. USA. 2005, v. 102 (41), p. 14789-14794.
  72. Portelli M., Sayers I. Genetic basis for personalized medicine in asthma. Expert Rev. Respir. Med. 2012, v. 6 (2), p. 223-236.
  73. Tse S.M., Tantisira K., Weiss S.T The pharmacogenetics and pharmacogenomics of asthma therapy. Pharmacogenomics J. 2011, v. 11 (6), p. 383-392.
  74. Kazani S., Wechsler M.E., Israel E. The role of pharmacogenomics in improving the management of asthma. J. Allergy Clin. Immunol. 2010, v. 125 (2), p. 295-302.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2012



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies